Immix Biopharma, Inc. (IMMX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$8.05

From 52W high−43.19%

Volume1.30M

Market cap$682.91M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$8.05

From 52W high

−43.19%

Volume

1.30M

Market cap

$682.91M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.3x

P/E (TTM)

—

RSI (14)

29.3

MomentumView details →

1D Return

+3.01%

YTD Return

+56.60%

SummaryUpdated Jun 1, 2026

Immix Biopharma, Inc. (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Los Angeles, California. The company went public in December 2021 and focuses on developing tissue-specific therapeutics for oncology and inflammatory diseases. Immix operates primarily in the United States and Australia, with its lead programs currently in various phases of clinical trials targeting cancer and inflammatory bowel diseases.

Ask drillr about Immix Biopharma, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−11.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−17.44%

ROA (TTM)

−16.69%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−12.82%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−17.11%

EBITDA YoY

−72.00%

MomentumView details →

1D Return

+3.01%

YTD Return

+56.60%

1Y Return

+166.78%

RSI (14)

29.3

vs 50D SMA

−29.59%

vs 200D SMA

−12.26%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

25.13x

Quick Ratio

25.13x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.18

EPS Surprise

−5.88%

Beats (12Q)

3/12

Next Q EPS Est

−$0.19

Avg Surprise (4Q)

−15.54%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−39.92M

Op. CF (TTM)

−38.50M

Next earningsNov 6, 2026 →

Latest newsMore news →

Immix Biopharma priced an underwritten registered offering of 11,363,637 common shares at $11.00 per share, expecting gross proceeds of $125 million and a close on or about September 30, 2026.21d ago

Immix Biopharma announced an interim update showing an 89% complete response rate across all NEXICART-2 patients, with MRD-negativity indicating a potential to reach up to 98% complete response rate in relapsed/refractory AL amyloidosis.21d ago

Similar companies

OmniAb, Inc.OABI Achieve Life Sciences, Inc.ACHV 4D Molecular Therapeutics, Inc.FDMT Wuhan YZY Biopharma Co Ltd02496.HK Ginkgo Bioworks Holdings, Inc.DNA Sana Biotechnology, Inc.SANA Find similar companies →

Latest newsMore news →

Immix Biopharma priced an underwritten registered offering of 11,363,637 common shares at $11.00 per share, expecting gross proceeds of $125 million and a close on or about September 30, 2026.21d ago Immix Biopharma announced an interim update showing an 89% complete response rate across all NEXICART-2 patients, with MRD-negativity indicating a potential to reach up to 98% complete response rate in relapsed/refractory AL amyloidosis.21d ago